With its recently granted expanded approval by the US Food and Drug Administration (FDA) for Gilead Sciences’ (Nasdaq: GILD) Trodelvy (sacituzumab govitecan-hziy) - for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies – the drug is expected to become a standard of care for these breast cancer patients, who have had limited treatment options.
This is Trodelvy’s second approval for breast cancer patients after it started being marketed for triple-negative breast cancer in 2021. Sales of the drug rose 79% from $380 million in 2021 to $680 million in 2022. GlobalData's analyst consensus forecasts project Trodelvy sales to reach 2.8 billion by 2028.
“Patients with HR+/HER2- metastatic breast cancer who are treated with hormone therapy and chemotherapy often develop resistance to these treatments. Trodelvy, an antibody-drug conjugate (ADC) that targets the Trop-2 protein found on the surface of most breast cancer cells, presents a statistically significant improvement in overall survival compared to retreating with chemotherapy,” commented GlobalData’ oncology and hematology analyst Israel Stern.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze